Sinphar Pharmaceutical Co Ltd Capital Reinvestment Ratio
Sinphar Pharmaceutical Co Ltd capital reinvestment ratio. Sinphar Pharmaceutical Co Ltd (1734) has a Capital Reinvestment Ratio of 0.87x as of March 2026, meaning it reinvests 1% of its operating cash flow (NT$116.42 Million) in capital expenditures (NT$101.07 Million). See free cash flow generation of Sinphar Pharmaceutical Co Ltd to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Sinphar Pharmaceutical Co Ltd (2003–2025)
Capital reinvestment ratio of Sinphar Pharmaceutical Co Ltd from 2003 to 2025. This chart tracks Sinphar Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 22 annual periods. See 1734 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Sinphar Pharmaceutical Co Ltd Capital Reinvestment Ratio by Year (2003–2025)
Sinphar Pharmaceutical Co Ltd capital reinvestment ratio by year from 2003 to 2025. For the full cash flow conversion analysis, see Sinphar Pharmaceutical Co Ltd cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.34x | NT$584.66 Million | NT$200.94 Million | ▼ -20.5% |
| 2024 | 0.43x | NT$593.51 Million | NT$256.71 Million | ▼ -57.4% |
| 2023 | 1.02x | NT$296.37 Million | NT$300.94 Million | ▲ +181.4% |
| 2022 | 0.36x | NT$425.30 Million | NT$153.44 Million | ▼ -69.7% |
| 2021 | 1.19x | NT$135.54 Million | NT$161.44 Million | ▲ +10.5% |
| 2020 | 1.08x | NT$146.39 Million | NT$157.77 Million | ▼ -66.5% |
| 2018 | 3.22x | NT$79.50 Million | NT$255.69 Million | ▲ +313.5% |
| 2017 | 0.78x | NT$219.87 Million | NT$171.00 Million | ▼ -69.8% |
| 2016 | 2.58x | NT$87.18 Million | NT$224.85 Million | ▲ +75.6% |
| 2015 | 1.47x | NT$280.53 Million | NT$412.04 Million | ▼ -25.8% |
| 2014 | 1.98x | NT$148.58 Million | NT$294.29 Million | ▼ -1.6% |
| 2013 | 2.01x | NT$297.09 Million | NT$598.16 Million | ▼ -11.8% |
| 2012 | 2.28x | NT$164.45 Million | NT$375.19 Million | ▲ +42.3% |
| 2011 | 1.60x | NT$225.58 Million | NT$361.69 Million | ▲ +43.2% |
| 2010 | 1.12x | NT$261.49 Million | NT$292.75 Million | ▲ +57.9% |
| 2009 | 0.71x | NT$309.94 Million | NT$219.71 Million | ▼ -17.6% |
| 2008 | 0.86x | NT$271.01 Million | NT$233.25 Million | ▼ -63.7% |
| 2007 | 2.37x | NT$174.85 Million | NT$414.90 Million | ▲ +58.5% |
| 2006 | 1.50x | NT$166.57 Million | NT$249.44 Million | ▼ -3.1% |
| 2005 | 1.55x | NT$122.09 Million | NT$188.76 Million | ▲ +68.1% |
| 2004 | 0.92x | NT$174.81 Million | NT$160.79 Million | ▼ -57.3% |
| 2003 | 2.16x | NT$120.84 Million | NT$260.50 Million | — |